Cargando…
Does mismatch negativity have utility for NMDA receptor drug development in depression?
Rapid antidepressant effects associated with ketamine have shifted the landscape for the development of therapeutics to treat major depressive disorder (MDD) from a monoaminergic to glutamatergic model. Treatment with ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, may be effective, bu...
Autores principales: | Murphy, Nicholas, Lijffijt, Marijn, Ramakrishnan, Nithya, Vo-Le, Bylinda, Vo-Le, Brittany, Iqbal, Sidra, Iqbal, Tabish, O’Brien, Brittany, Smith, Mark A., Swann, Alan C., Mathew, Sanjay J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Psiquiatria
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827377/ https://www.ncbi.nlm.nih.gov/pubmed/33825765 http://dx.doi.org/10.1590/1516-4446-2020-1685 |
Ejemplares similares
-
A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-d-aspartate receptor blockade in healthy veterans
por: Murphy, Nicholas, et al.
Publicado: (2020) -
A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD
por: Lijffijt, Marijn, et al.
Publicado: (2019) -
Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression
por: O'Brien, Brittany, et al.
Publicado: (2019) -
Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
por: Murphy, Nicholas, et al.
Publicado: (2023) -
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial
por: Murphy, Nicholas, et al.
Publicado: (2023)